Companies Sotera Health Co
Sotera Health (SHC): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Sotera Health Co’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers47th pct.Of 19 peer CEOs
CEO pay, last three years
- $9,701,005FY2023
- $10,392,468FY2024
- $10,656,063FY2025
CEO total pay was $10,656,063 in fiscal 2025, up from $10,392,468 in fiscal 2024.
FY2025: salary $1,130,699 · bonus $0 · stock awards $8,022,400 · option awards $0
Executives and directors
Jonathan Lyons · CFOAlexander Dimitrief · General CounselMichael Petras · CEOMichael Rutz · PresidentAnn R. Klee · Independent DirectorChristopher A. Simon · Independent DirectorConstantine S. Mihas · Independent DirectorDavid A. Donnini · DirectorDavid E. Wheadon, M.D · Independent DirectorJames C. Neary · Independent DirectorKaren A. Flynn · Independent DirectorKenneth D. Krause · Independent DirectorRichard G. Kyle · Independent DirectorRobert B. Knauss · Independent DirectorRuoxi Chen · Independent DirectorSean L. Cunningham · Independent DirectorVincent K. Petrella · Lead Independent Director
Frequently asked questions
Who was the highest-paid executive at Sotera Health Co in fiscal 2025?
As disclosed, Michael Petras (Chairman and CEO) was the highest-paid executive at Sotera Health Co in fiscal 2025, with total compensation of $10,656,063.
How does Sotera Health Co's chief executive pay compare to its disclosed peer group?
As disclosed, Michael Petras's total compensation ranked at the 47th percentile of Sotera Health Co's disclosed peer group.
What is Sotera Health Co's CEO-to-median employee pay ratio?
As disclosed, Sotera Health Co's CEO-to-median employee pay ratio was 129:1.
How did shareholders vote on Sotera Health Co's executive compensation?
As disclosed, 97.49% of shareholders supported Sotera Health Co's executive compensation in the latest say-on-pay vote.
How much does Sotera Health Co spend in total on board compensation for fiscal 2025?
As disclosed, Sotera Health Co reported total board compensation of $3,310,580 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Michael Petras | $1,130,699 | $0 | $8,022,400 | $0 | $1,484,890 | $0 | $18,074 | $10,656,063 |
| Chairman and CEO | ||||||||
| Jonathan Lyons | 536,539 | 50,000 | 2,087,272 | 0 | 394,581 | 0 | 17,991 | 3,086,383 |
| Senior Vice President, Chief Financial Officer | ||||||||
| Alexander Dimitrief | 600,000 | 0 | 1,547,623 | 0 | 309,000 | 0 | 2,989 | 2,459,612 |
| Former SVP and General Counsel | ||||||||
| Michael Rutz | 500,000 | 0 | 1,341,266 | 0 | 320,250 | 0 | 18,513 | 2,180,029 |
| President of Sterigenics | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Michael Petras | $10,656,063 | $10,392,468 | $9,701,005 | ↑ +263,595 |
| Jonathan Lyons | 3,086,383 | 2,138,672 | 2,177,576 | ↑ +947,711 |
| Alexander Dimitrief | 2,459,612 | 2,390,971 | 862,177 | ↑ +68,641 |
| Michael Rutz | 2,180,029 | 2,481,509 | 2,030,239 | ↓ −301,480 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The Company's executive compensation program is designed to align the interests of executives with stockholders, paying for performance with a majority of compensation being contingent, balancing short-term and long-term goals, and providing competitive compensation to attract and retain top talent.
| CEO STI target (% of salary) | 125% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Exequity, LLP |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | True |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Jonathan Lyons | RSU | 2025-03-03 | — | — | 59,790 | — | $698,347 |
| Jonathan Lyons | PSU | 2025-03-03 | 11,958 | 59,790 | — | 119,580 | 698,347 |
| Alexander Dimitrief | PSU | 2025-03-03 | 11,211 | 56,053 | — | 112,106 | 654,699 |
| Alexander Dimitrief | RSU | 2025-03-03 | — | — | 56,053 | — | 654,699 |
| Jonathan Lyons | RSU | 2025-03-03 | — | — | 37,369 | — | 436,470 |
| Alexander Dimitrief | PSU | 2025-03-03 | — | — | — | 28,026 | 238,225 |
| Jonathan Lyons | PSU | 2025-03-03 | — | — | — | 29,895 | 254,108 |
| Michael Petras | PSU | 2025-03-03 | — | — | — | 149,476 | 1,038,858 |
| Michael Petras | RSU | 2025-03-03 | — | — | 298,953 | — | 3,491,771 |
| Michael Rutz | PSU | 2025-03-03 | — | — | — | 24,289 | 206,461 |
| Michael Petras | PSU | 2025-03-03 | 59,791 | 298,953 | — | 597,906 | 3,491,771 |
| Michael Rutz | RSU | 2025-03-03 | — | — | 48,579 | — | 567,403 |
| Michael Rutz | PSU | 2025-03-03 | 9,716 | 48,579 | — | 97,158 | 567,403 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Jonathan Lyons | $1,134,817 | $952,455 | $0 | 45.6% |
| Alexander Dimitrief | 654,699 | 892,924 | 0 | 57.7% |
| Michael Petras | 3,491,771 | 4,530,629 | 0 | 56.5% |
| Michael Rutz | 567,403 | 773,864 | 0 | 57.7% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Jonathan Lyons | RSU | 5,921 | — | $104,446 |
| Michael Rutz | RSU | 9,475 | — | 167,139 |
| Michael Rutz | PSU | 9,716 | — | 171,390 |
| Alexander Dimitrief | PSU | 11,211 | — | 197,762 |
| Jonathan Lyons | Option | 11,214 | 16.89 | — |
| Jonathan Lyons | PSU | 11,958 | — | 210,939 |
| Michael Rutz | Option | 17,961 | 17.59 | — |
| Jonathan Lyons | RSU | 19,736 | — | 348,143 |
| Michael Rutz | RSU | 22,847 | — | 403,021 |
| Michael Rutz | PSU | 24,289 | — | 428,458 |
| Jonathan Lyons | RSU | 27,416 | — | 483,618 |
| Alexander Dimitrief | PSU | 28,026 | — | 494,379 |
| Jonathan Lyons | PSU | 29,895 | — | 527,348 |
| Alexander Dimitrief | RSU | 34,270 | — | 604,523 |
| Jonathan Lyons | RSU | 37,369 | — | 659,189 |
| Michael Rutz | Option | 45,376 | 14.59 | — |
| Michael Rutz | RSU | 48,579 | — | 856,934 |
| Jonathan Lyons | Option | 54,451 | 14.59 | — |
| Alexander Dimitrief | RSU | 56,053 | — | 988,775 |
| Jonathan Lyons | RSU | 59,790 | — | 1,054,696 |
| Michael Petras | PSU | 59,791 | — | 1,054,713 |
| Alexander Dimitrief | Option | 68,064 | 14.59 | — |
| Michael Petras | RSU | 71,063 | — | 1,253,551 |
| Michael Petras | Option | 134,698 | 17.59 | — |
| Michael Petras | PSU | 149,476 | — | 2,636,757 |
| Michael Petras | RSU | 182,774 | — | 3,224,133 |
| Michael Petras | RSU | 298,953 | — | 5,273,531 |
| Michael Petras | Option | 363,006 | 14.59 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Vincent K. PetrellaIndependent · Lead Independent Director · Audit (Chair) · EO Litigation · Nordion Pricing | $165,000 | $234,558 | $0 | $0 | $0 | $399,558 |
| Christopher A. SimonIndependent · LDC · Leadership Development and Compensation | 105,000 | 234,558 | 0 | 0 | 0 | 339,558 |
| Sean L. CunninghamIndependent · NCG · Nominating/Governance · EO Litigation · Nordion Pricing | 102,500 | 234,558 | 0 | 0 | 0 | 337,058 |
| Ann R. KleeIndependent · Audit · NCG (Chair) · Nominating/Governance (Chair) · EO Litigation | 97,500 | 234,558 | 0 | 0 | 0 | 332,058 |
| James C. NearyIndependent · LDC (Chair) · Leadership Development and Compensation (Chair) | 95,000 | 234,558 | 0 | 0 | 0 | 329,558 |
| David E. Wheadon, M.DIndependent · Audit · NCG · Nominating/Governance · Partial-year service | 85,000 | 234,558 | 0 | 0 | 0 | 319,558 |
| Karen A. FlynnIndependent · Audit · Nordion Pricing | 82,500 | 234,558 | 0 | 0 | 0 | 317,058 |
| Constantine S. MihasIndependent | 80,000 | 234,558 | 0 | 0 | 0 | 314,558 |
| Ruoxi ChenIndependent · NCG · Nominating/Governance · Nordion Pricing | 77,500 | 234,558 | 0 | 0 | 0 | 312,058 |
| Robert B. KnaussIndependent · EO Litigation | 75,000 | 234,558 | 0 | 0 | 0 | 309,558 |
| David A. DonniniNot independent | 0 | 0 | 0 | 0 | 0 | 0 |
| Richard G. KyleIndependent · LDC · NCG · Leadership Development and Compensation · Nominating/Governance · Partial-year service · Newly elected | 0 | 0 | 0 | 0 | 0 | 0 |
| Kenneth D. KrauseIndependent · Audit · EO Litigation · Partial-year service · Newly elected | 0 | 0 | 0 | 0 | 0 | 0 |
| Michael B. Petras JrEmployee director · Board Chair | 0 | 0 | 0 | — | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $75,000 |
|---|---|
| Annual equity retainer | $225,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 25,000 / 20,000 / 15,000 |
| Stock ownership guideline | ensures our executive team and non-employee directors are complying with our stock ownership guidelines; |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $965,000 |
| Equity awards (grant-date value) | $2,345,580 |
| All other compensation | $0 |
| Total cost of the board | $3,310,580 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Sotera Health as a peer
Companies that benchmark against SHC
13 companies name SHC as a compensation peer
The list of companies that name SHC as a peer is temporarily unavailable — recheck shortly.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
MASI Masimo CorporationIART Integra LifeSciences Holdings CorporationRMD ResMed Inc.HAE Haemonetics CorporationAVNS Avanos Medical, Inc.MRVI Maravai LifeSciences Holdings, Inc.TECH Bio-Techne CorporationCNMD CONMED CorporationMEDP Medpace Holdings, Inc.TNDM Tandem Diabetes Care, Inc.COO The Cooper Companies, Inc.MMSI Merit Medical Systems, Inc.TFX Teleflex IncorporatedQDEL QuidelOrtho CorporationWAT Waters CorporationHOLX Hologic, Inc.RGEN Repligen CorporationWST West Pharmaceutical Services, Inc.STE STERIS plc
Peer reciprocity
The companies Sotera Health Co names as compensation peers that name it back in their own disclosed peer groups.
Maravai LifeSciences Holdings, Inc. (MRVI)79Medpace Holdings, Inc. (MEDP)80QuidelOrtho Corporation (QDEL)81
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Masimo Corporation | 2025 | Catherine Szyman | $850,048 | $16,388,693 | $1,399,998 | $1,130,000 | $19,797,140 |
| 2 | ResMed Inc. | 2026 | Michael Farrell | 1,272,895 | 9,749,468 | 3,249,907 | 1,738,857 | 16,201,649 |
| 3 | The Cooper Companies, Inc. | 2025 | Albert White III | 1,170,769 | 6,642,918 | 6,643,050 | 1,525,951 | 16,051,141 |
| 4 | Hologic, Inc. | 2024 | Stephen MacMillan | 1,212,628 | 9,141,468 | 2,937,477 | 1,990,413 | 15,819,261 |
| 5 | Waters Corporation | 2025 | Udit Batra | 1,150,000 | 7,430,247 | 2,999,922 | 2,371,875 | 13,973,044 |
| 6 | Merit Medical Systems, Inc. | 2025 | Fred Lampropoulos | 1,890,000 | 9,313,606 | 0 | 1,882,894 | 13,755,143 |
| 7 | Haemonetics Corporation | 2026 | Christopher Simon | 1,100,008 | 7,561,987 | 1,504,968 | 1,834,250 | 12,044,701 |
| 8 | Steris plc | 2026 | Daniel Carestio | 1,095,707 | 4,333,951 | 4,334,251 | 1,725,007 | 11,508,522 |
| 9 | Medpace Holdings, Inc. | 2025 | August Troendle | 937,417 | 0 | 9,999,999 | 0 | 11,443,766 |
| 10 | QuidelOrtho Corporation | 2025 | Brian Blaser | 1,000,000 | 8,965,822 | 0 | 1,274,500 | 11,255,782 |
| 11 | Sotera Health Co | 2025 | Michael Petras | 1,130,699 | 8,022,400 | 0 | 1,484,890 | 10,656,063 |
| 12 | Maravai LifeSciences Holdings, Inc. | 2025 | Bernd Brust | 388,863 | 7,660,000 | 1,460,000 | 425,343 | 10,129,708 |
| 13 | Avanos Medical, Inc. | 2025 | David Pacitti | 751,705 | 7,000,000 | 0 | 1,148,667 | 9,469,803 |
| 14 | Integra LifeSciences Holdings Corporation | 2025 | Mojdeh Poul | 1,009,616 | 5,219,868 | 2,250,011 | 174,563 | 9,375,551 |
| 15 | Bio-Techne Corporation | 2025 | Kim Kelderman | 936,000 | 3,929,942 | 1,932,848 | 1,318,917 | 8,151,181 |
| 16 | Conmed Corporation | 2025 | Patrick Beyer | 891,100 | 2,499,971 | 2,499,977 | 1,129,469 | 7,634,873 |
| 17 | West Pharmaceutical Services, Inc. | 2025 | Eric Green | 1,177,290 | 3,327,048 | 1,108,961 | 1,471,613 | 7,190,876 |
| 18 | Tandem Diabetes Care, Inc. | 2025 | John Sheridan | 790,583 | 5,367,796 | 0 | 674,090 | 6,858,503 |
| 19 | Teleflex Incorporated | 2025 | Liam Kelly | 1,144,400 | 2,005,604 | 2,886,518 | 227,280 | 6,732,419 |
| 20 | Repligen Corporation | 2025 | Olivier Loeillot | 860,000 | 3,374,853 | 1,095,626 | 774,000 | 6,114,771 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Sotera Health Co | 103% | PSU 40 · RSU 40 · Other 20 | No | Exequity, LLP |
| Avanos Medical, Inc. | 139% | PSU 50 · RSU 25 · Options 25 | No | Meridian Compensation Partners |
| Bio-Techne Corporation | 128.1% | PSU 50 · Options 25 · RSU 25 | No | Aon |
| Conmed Corporation | 126.8% | Options 50 · PSU 50 | Yes — rTSR | Compensia, Inc. |
| Haemonetics Corporation | 133.4% | PSU 60 · RSU 20 · Options 20 | Yes — Relative Total Shareholder Return (rTSR) | Pearl Meyer & Partners, LLC |
| Hologic, Inc. | 109% | PSU 50 · RSU 25 · Option 25 | No | Pearl Meyer & Partners, LLC |
| Integra LifeSciences Holdings Corporation | 40% | PSU 50 · Options 25 · RSU 25 | No | WTW |
| Maravai LifeSciences Holdings, Inc. | not disclosed | not disclosed | No | Meridian Compensation Partners, LLC |
| Masimo Corporation | not disclosed | not disclosed | not disclosed | FW Cook |
| Medpace Holdings, Inc. | 52.5% | Options 100 | not disclosed | Total Compensation Solutions (TCS) |
| Merit Medical Systems, Inc. | 124.53% | PSU 60 · RSU 40 | Yes — Relative Total Shareholder Return (rTSR) | Pearl Meyer & Partners, LLC |
| QuidelOrtho Corporation | not disclosed | PSU 60 · RSU 40 | Yes — Total Shareholder Return (TSR) | Compensia |
| Repligen Corporation | 100% | RSU 50 · PSU 25 · Options 25 | No | Meridian Compensation Partners, LLC |
| ResMed Inc. | not disclosed | PSU 50 · RSU 25 · Options 25 | Yes — Relative TSR | FW Cook |
| Steris plc | 125.1% | Option 50 · Restricted Stock 50 | not disclosed | Frederic W. Cook & Co., Inc. |
| Tandem Diabetes Care, Inc. | 87% | PSU 50 · RSU 50 | Yes — TSR performance compared to the Russell 3000 index in the three-year period between 2025 and 2027 | WTW |
| Teleflex Incorporated | 25.9% | Options 55 · RSU 25 · PSU 20 | Yes — Absolute TSR | FW Cook |
| The Cooper Companies, Inc. | 100.9% | Options 50 · PSU 50 | No | Compensia |
| Waters Corporation | 110% | PSU 50 · Options 35 · RSU 15 | Yes — Relative Total Shareholder Return (rTSR) | Pearl Meyer |
| West Pharmaceutical Services, Inc. | 100% | PSU 50 · RSU 25 · Options 25 | No | Pay Governance |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-05-21 | 257,678,396 | 6,586,053 | 51,797 | 97.49% | Passed |
| 2025 | 2025-05-21 | 272,812,479 | 1,865,802 | 290,022 | 99.22% | Passed |
| 2024 | 2024-05-23 | 267,658,420 | 5,255,645 | 44,839 | 98.06% | Passed |
| 2023 | 2023-05-25 | 229,154,947 | 38,382,040 | 112,899 | 85.65% | Passed |
| 2021 | 2021-05-27 | — | — | — | — | — |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-05-21 | 97.49%a |
| 2025 | 2025-05-21 | 99.22%b |
| 2024 | 2024-05-23 | 98.06%c |
a. Approved under the standard stated in the filing — “Approval, on an advisory basis, of the compensation of our named executive officers FOR, AGAINST or ABSTAIN Majority of the shares present or represented by proxy and entitled to vote on the subject matter Broker non-votes will have no effect -- not counted as a "vote cast" Abstentions will have the effect of a "vote against" No Yes 3.”.
b. Approved under the standard stated in the filing — “Approval, on an advisory basis, of the compensation of our named executive officers FOR, AGAINST or ABSTAIN Majority of the shares present or represented by proxy and entitled to vote on the subject matter Broker non-votes will have no effect -- not counted as a "vote cast" Abstentions will have the effect of a "vote against" No Yes 3.”.
c. Approved under the standard stated in the filing — “Broker non-votes will have no effect — not counted as a "vote cast" Abstentions will have the effect of a "vote against"”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 129 : 1 |
|---|---|
| CEO total compensation | $10,656,063 |
| Median employee compensation | $82,784 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| GTCR INVESTMENT XI LLC | Director | 2026-05-13 | D | 12,735,301 | $15 | $193,169,046 | Common, indirect | Form 4 ↗ |
| WARBURG PINCUS & CO. | Director | 2026-05-13 | D | 19,102,952 | 15 | 289,753,576 | Common, indirect | Form 4 ↗ |
| WARBURG PINCUS & CO. | Director | 2026-05-13 | D | 19,102,952 | 15 | 289,753,576 | Common, indirect | Form 4 ↗ |
| David E. Wheadon | Director | 2026-05-22 | A | 14,970 | 0 | 0 | RSU | Form 4 ↗ |
| Simon, Christopher | Director | 2026-05-22 | A | 14,970 | 0 | 0 | RSU | Form 4 ↗ |
| James C. Neary | Director | 2026-05-22 | A | 14,970 | 0 | 0 | RSU | Form 4 ↗ |
| Richard G. Kyle | Director | 2026-05-22 | A | 14,970 | 0 | 0 | RSU | Form 4 ↗ |
| Ruoxi Chen | Director | 2026-05-22 | A | 14,970 | 0 | 0 | RSU | Form 4 ↗ |
| Vincent K. Petrella | Director | 2026-05-22 | A | 14,970 | 0 | 0 | RSU | Form 4 ↗ |
| Sean L. Cunningham | Director | 2026-05-22 | A | 14,970 | 0 | 0 | RSU | Form 4 ↗ |
| Kenneth D. Krause | Director | 2026-05-22 | A | 14,970 | 0 | 0 | RSU | Form 4 ↗ |
| Ann R. Klee | Director | 2026-05-22 | A | 14,970 | 0 | 0 | RSU | Form 4 ↗ |
| Karen A. Flynn | Director | 2026-05-22 | A | 14,970 | 0 | 0 | RSU | Form 4 ↗ |
| Alton Shader | Director | 2026-05-26 | A | 375,939 | 0 | 0 | Common | Form 4 ↗ |
| Alton Shader | Director | 2026-05-26 | A | 203,634 | 0 | 0 | Common | Form 4 ↗ |
| Alton Shader | Director | 2026-05-26 | A | 101,817 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jonathan Lyons | Sr. Vice President, CFO | 2026-08-05 | D | 11,316 | 18 | 203,462 | Common | Form 4 ↗ |
| Michael Rutz | President of Sterigenics | 2026-08-07 | D | 150,000 | 19 | 2,825,250 | Common | Form 4 ↗ |
| Michael B. Petras Jr. | Director | 2026-08-17 | D | 850,000 | 19 | 15,725,935 | Common | Form 4 ↗ |
| Michael B. Petras Jr. | Director | 2026-08-17 | D | 294,515 | 19 | 5,448,851 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (81 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Michael Petras. DEF 14A, filed 2026-04-08. Section “2025 Summary Compensation Table” · page 54. As printed: 10,656,063. View filing ↗
- Section 01, Jonathan Lyons. DEF 14A, filed 2026-04-08. Section “2025 Summary Compensation Table” · page 54. As printed: 3,086,383. View filing ↗
- Section 01, Alexander Dimitrief. DEF 14A, filed 2026-04-08. Section “2025 Summary Compensation Table” · page 54. As printed: 2,459,612. View filing ↗
- Section 01, Michael Rutz. DEF 14A, filed 2026-04-08. Section “2025 Summary Compensation Table” · page 54. As printed: 2,180,029. View filing ↗
- Section 03, Jonathan Lyons RSU. DEF 14A, filed 2026-04-08. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Jonathan Lyons PSU. DEF 14A, filed 2026-04-08. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Alexander Dimitrief PSU. DEF 14A, filed 2026-04-08. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Alexander Dimitrief RSU. DEF 14A, filed 2026-04-08. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Jonathan Lyons RSU. DEF 14A, filed 2026-04-08. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Alexander Dimitrief PSU. DEF 14A, filed 2026-04-08. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Jonathan Lyons PSU. DEF 14A, filed 2026-04-08. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Michael Petras PSU. DEF 14A, filed 2026-04-08. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Michael Petras RSU. DEF 14A, filed 2026-04-08. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Michael Rutz PSU. DEF 14A, filed 2026-04-08. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Michael Petras PSU. DEF 14A, filed 2026-04-08. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Michael Rutz RSU. DEF 14A, filed 2026-04-08. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Michael Rutz PSU. DEF 14A, filed 2026-04-08. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2026-04-08. Section “CEO Pay Ratio”. As printed: 129 : 1. View filing ↗
- Section 08, Vincent K. Petrella. DEF 14A, filed 2026-04-08. Section “Director Compensation”. As printed: 399,558. View filing ↗
- Section 08, Christopher A. Simon. DEF 14A, filed 2026-04-08. Section “Director Compensation”. As printed: 339,558. View filing ↗
- Section 08, Sean L. Cunningham. DEF 14A, filed 2026-04-08. Section “Director Compensation”. As printed: 337,058. View filing ↗
- Section 08, Ann R. Klee. DEF 14A, filed 2026-04-08. Section “Director Compensation”. As printed: 332,058. View filing ↗
- Section 08, James C. Neary. DEF 14A, filed 2026-04-08. Section “Director Compensation”. As printed: 329,558. View filing ↗
- Section 08, David E. Wheadon, M.D. DEF 14A, filed 2026-04-08. Section “Director Compensation”. As printed: 319,558. View filing ↗
- Section 08, Karen A. Flynn. DEF 14A, filed 2026-04-08. Section “Director Compensation”. As printed: 317,058. View filing ↗
- Section 08, Constantine S. Mihas. DEF 14A, filed 2026-04-08. Section “Director Compensation”. As printed: 314,558. View filing ↗
- Section 08, Ruoxi Chen. DEF 14A, filed 2026-04-08. Section “Director Compensation”. As printed: 312,058. View filing ↗
- Section 08, Robert B. Knauss. DEF 14A, filed 2026-04-08. Section “Director Compensation”. As printed: 309,558. View filing ↗
- Section 08, David A. Donnini. DEF 14A, filed 2026-04-08. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Richard G. Kyle. DEF 14A, filed 2026-04-08. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Kenneth D. Krause. DEF 14A, filed 2026-04-08. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Michael B. Petras Jr. DEF 14A, filed 2026-04-08. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, GTCR INVESTMENT XI LLC 2026-05-13. Form 4, filed 2026-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, WARBURG PINCUS & CO. 2026-05-13. Form 4, filed 2026-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, WARBURG PINCUS & CO. 2026-05-13. Form 4, filed 2026-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David E. Wheadon 2026-05-22. Form 4, filed 2026-05-27. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Simon, Christopher 2026-05-22. Form 4, filed 2026-05-27. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James C. Neary 2026-05-22. Form 4, filed 2026-05-27. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Richard G. Kyle 2026-05-22. Form 4, filed 2026-05-27. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ruoxi Chen 2026-05-22. Form 4, filed 2026-05-27. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Vincent K. Petrella 2026-05-22. Form 4, filed 2026-05-27. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sean L. Cunningham 2026-05-22. Form 4, filed 2026-05-27. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kenneth D. Krause 2026-05-22. Form 4, filed 2026-05-27. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ann R. Klee 2026-05-22. Form 4, filed 2026-05-27. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Karen A. Flynn 2026-05-22. Form 4, filed 2026-05-27. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alton Shader 2026-05-26. Form 4, filed 2026-05-27. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alton Shader 2026-05-26. Form 4, filed 2026-05-27. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Alton Shader 2026-05-26. Form 4, filed 2026-05-27. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jonathan Lyons 2026-08-05. Form 4, filed 2026-08-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Rutz 2026-08-07. Form 4, filed 2026-08-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael B. Petras Jr. 2026-08-17. Form 4, filed 2026-08-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael B. Petras Jr. 2026-08-17. Form 4, filed 2026-08-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-05-22. Item 5.07 · say-on-pay result. As reported: 97.49% (votes for as printed: 257,678,396). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-05-23. Item 5.07 · say-on-pay result. As reported: 99.22% (votes for as printed: 272,812,479). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-05-24. Item 5.07 · say-on-pay result. As reported: 98.06% (votes for as printed: 267,658,420). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 965,000 + equity 2,345,580 + all other 0 = 3,310,580, summed across the director compensation table rows.
- Masimo Corporation, Section 10b CEO total. 10-K/A, filed 2026-05-01. CEO total compensation as printed in Masimo Corporation's own proxy. As printed: 19,797,140. View filing ↗
- ResMed Inc., Section 10b CEO total. DEF 14A, filed 2026-10-01. CEO total compensation as printed in ResMed Inc.'s own proxy. As printed: 16,201,649. View filing ↗
- The Cooper Companies, Inc., Section 10b CEO total. DEF 14A, filed 2026-02-24. CEO total compensation as printed in The Cooper Companies, Inc.'s own proxy. As printed: 16,051,141. View filing ↗
- Hologic, Inc., Section 10b CEO total. DEF 14A, filed 2025-01-16. CEO total compensation as printed in Hologic, Inc.'s own proxy. As printed: 15,819,261. View filing ↗
- Waters Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-09. CEO total compensation as printed in Waters Corporation's own proxy. As printed: 13,973,044. View filing ↗
- Merit Medical Systems, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-31. CEO total compensation as printed in Merit Medical Systems, Inc.'s own proxy. As printed: 13,755,143. View filing ↗
- Haemonetics Corporation, Section 10b CEO total. DEF 14A, filed 2026-06-09. CEO total compensation as printed in Haemonetics Corporation's own proxy. As printed: 12,044,701. View filing ↗
- Steris plc, Section 10b CEO total. DEF 14A, filed 2026-06-11. CEO total compensation as printed in Steris plc's own proxy. As printed: 11,508,522. View filing ↗
- Medpace Holdings, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-01. CEO total compensation as printed in Medpace Holdings, Inc.'s own proxy. As printed: 11,443,766. View filing ↗
- QuidelOrtho Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in QuidelOrtho Corporation's own proxy. As printed: 11,255,782. View filing ↗
- Sotera Health Co (subject), Section 10b CEO total. DEF 14A, filed 2026-04-08. CEO total compensation as printed in Sotera Health Co's own proxy. As printed: 10,656,063. View filing ↗
- Maravai LifeSciences Holdings, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Maravai LifeSciences Holdings, Inc.'s own proxy. As printed: 10,129,708. View filing ↗
- Avanos Medical, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-12. CEO total compensation as printed in Avanos Medical, Inc.'s own proxy. As printed: 9,469,803. View filing ↗
- Integra LifeSciences Holdings Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in Integra LifeSciences Holdings Corporation's own proxy. As printed: 9,375,551. View filing ↗
- Bio-Techne Corporation, Section 10b CEO total. DEF 14A, filed 2025-09-19. CEO total compensation as printed in Bio-Techne Corporation's own proxy. As printed: 8,151,181. View filing ↗
- Conmed Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-07. CEO total compensation as printed in Conmed Corporation's own proxy. As printed: 7,634,873. View filing ↗
- West Pharmaceutical Services, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-12. CEO total compensation as printed in West Pharmaceutical Services, Inc.'s own proxy. As printed: 7,190,876. View filing ↗
- Tandem Diabetes Care, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-07. CEO total compensation as printed in Tandem Diabetes Care, Inc.'s own proxy. As printed: 6,858,503. View filing ↗
- Teleflex Incorporated, Section 10b CEO total. DEF 14A, filed 2026-04-13. CEO total compensation as printed in Teleflex Incorporated's own proxy. As printed: 6,732,419. View filing ↗
- Repligen Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-02. CEO total compensation as printed in Repligen Corporation's own proxy. As printed: 6,114,771. View filing ↗
- Section 10a, Maravai LifeSciences Holdings, Inc. reciprocity. DEF 14A. Maravai LifeSciences Holdings, Inc. names Sotera Health Co in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Medpace Holdings, Inc. reciprocity. DEF 14A. Medpace Holdings, Inc. names Sotera Health Co in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, QuidelOrtho Corporation reciprocity. DEF 14A. QuidelOrtho Corporation names Sotera Health Co in its own disclosed peer group (read from its most recent proxy). View filing ↗